Palmitoylethanolamide (PEA) in the treatment of restless legs syndrome: Rationale and case report
Case seriesHumans
- Design
- Case series
- Subjects
- 1 patient, already taking gabapentin for restless legs syndrome
- Dose used in the study
- Oral palmitoylethanolamide, added to the patient's existing gabapentin
- Duration
- Not stated in the abstract
- What was measured
- The intensity of restless legs syndrome's painful symptoms.
What the authors reported
The author reports the patient's painful restless legs symptoms decreased in intensity after starting palmitoylethanolamide alongside gabapentin, with no adverse events. The author frames this as the first published report of palmitoylethanolamide used for restless legs syndrome, and notes palmitoylethanolamide is already reported to reduce pain in other central and peripheral neurological conditions, such as migraine and peripheral neuropathy.
Limits of this study
A single case report, not a trial: no control, no way to separate the effect of palmitoylethanolamide from gabapentin, natural fluctuation in symptoms, or placebo response. Dose and duration are not given in the abstract.
Source
PubMed 41504926 · doi:10.1007/s10072-025-08677-8
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.